Equities

Sagimet Biosciences Inc

Sagimet Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.50
  • Today's Change-0.02 / -0.44%
  • Shares traded502.83k
  • 1 Year change+38.89%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

  • Revenue in USD (TTM)0.00
  • Net income in USD-37.52m
  • Incorporated2006
  • Employees10.00
  • Location
    Sagimet Biosciences Inc155 BOVET RD., SUITE 303SAN MATEO 94402United StatesUSA
  • Phone+1 (650) 561-8600
  • Fax+1 (302) 730-1370
  • Websitehttps://sagimet.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inhibikase Therapeutics Inc0.00-19.57m133.04m8.00---------2.72-2.720.00-0.07110.00----0.00-175.81-66.49-267.87-85.55-------1,139.14--------111.03-42.21-5.40------
Black Diamond Therapeutics Inc0.00-73.10m137.50m54.00--1.41-----1.36-1.360.001.720.00----0.00-47.12-40.29-53.28-43.29------------0.00------9.57---15.37--
Vaxart Inc16.76m-72.34m138.24m109.00--2.02--8.25-0.4182-0.41820.09280.30090.1231--8.18153,761.50-53.13-49.60-80.07-54.86-----431.61-1,398.00---189.180.0665--6,796.2612.1523.47--21.49--
TuHURA Biosciences Inc0.00-8.50m138.28m1.00---------75.24-75.240.002.380.00----0.00-163.44-224.08-343.80-346.74------------0.00------43.40------
Seres Therapeutics Inc64.00k-165.29m138.53m233.00--5.79--2,164.47-1.14-0.22710.00040.14050.0002----274.68-60.50-41.51-82.15-54.13-----258,259.40-170.14---20.450.00--1,672.2434.9154.54--32.72--
CytoDyn Inc0.00-20.53m141.87m9.00---------0.0241-0.02410.00-0.06990.00----0.00-94.20-259.15-----------232,918.20--1.36--------35.70------
Acumen Pharmaceuticals Inc0.00-81.67m142.39m51.00--0.6556-----1.37-1.370.003.620.00----0.00-29.52---30.98--------------0.1202-------22.20------
PepGen Inc0.00-87.23m143.42m64.00--1.04-----2.98-2.980.004.220.00----0.00-52.16---58.79--------------0.00-------13.78------
Sagimet Biosciences Inc0.00-37.52m145.52m10.00--0.8526-----1.29-1.290.005.300.00----0.00-27.02---27.94--------------0.00------8.60------
Achieve Life Sciences Inc0.00-32.94m147.84m22.00--4.72-----1.13-1.130.000.91240.00----0.00-91.19-86.31-107.21-119.59-----------22.540.2384------29.60---14.51--
Atossa Therapeutics Inc0.00-26.91m150.91m10.00--2.05-----0.2144-0.21440.000.58570.00----0.00-29.71-29.97-31.30-32.55------------0.00-------11.62---33.90--
Instil Bio Inc0.00-75.17m151.93m49.00--0.8645-----11.56-11.560.0027.020.00----0.00-24.53---25.52-------------492.200.3179------30.06------
Gossamer Bio Inc105.32m-71.65m157.83m135.00--2.92--1.50-0.3283-0.32830.45950.23890.3014----780,162.90-20.51-57.43-23.67-64.38-----68.03-----6.840.7847------21.61------
2Seventy Bio Inc45.62m-94.55m160.16m274.00--0.7023--3.51-1.85-1.850.86594.430.0797--2.18166,496.30-16.52---18.31--65.7291.76-207.25-223.57----0.00--9.7212.9614.39---22.88--
Data as of Nov 21 2024. Currency figures normalised to Sagimet Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

35.12%Per cent of shares held by top holders
HolderShares% Held
Point72 Asset Management LPas of 30 Sep 20242.39m7.80%
Baker Bros. Advisors LPas of 30 Sep 20241.38m4.51%
Alyeska Investment Group LPas of 30 Sep 20241.38m4.49%
Citadel Advisors LLCas of 30 Sep 20241.20m3.90%
The Vanguard Group, Inc.as of 30 Sep 20241.04m3.39%
Rock Springs Capital Management LPas of 30 Sep 2024787.81k2.57%
BlackRock Advisors LLCas of 30 Sep 2024733.02k2.39%
HHLR Advisors Ltd.as of 30 Sep 2024724.80k2.36%
PFM Health Sciences LPas of 30 Sep 2024649.01k2.12%
Bank of America, NA (Private Banking)as of 30 Sep 2024488.55k1.59%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.